Flora Growth (FLGC) Competitors $0.66 -0.01 (-0.75%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends FLGC vs. GANX, RPTX, AADI, VTVT, ALXO, ALVR, ANEB, OKYO, PDSB, and NBRVShould you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include Gain Therapeutics (GANX), Repare Therapeutics (RPTX), Aadi Bioscience (AADI), vTv Therapeutics (VTVT), ALX Oncology (ALXO), AlloVir (ALVR), Anebulo Pharmaceuticals (ANEB), OKYO Pharma (OKYO), PDS Biotechnology (PDSB), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. Flora Growth vs. Gain Therapeutics Repare Therapeutics Aadi Bioscience vTv Therapeutics ALX Oncology AlloVir Anebulo Pharmaceuticals OKYO Pharma PDS Biotechnology Nabriva Therapeutics Gain Therapeutics (NASDAQ:GANX) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations. Does the media refer more to GANX or FLGC? In the previous week, Gain Therapeutics had 7 more articles in the media than Flora Growth. MarketBeat recorded 9 mentions for Gain Therapeutics and 2 mentions for Flora Growth. Flora Growth's average media sentiment score of 1.46 beat Gain Therapeutics' score of 0.83 indicating that Flora Growth is being referred to more favorably in the news media. Company Overall Sentiment Gain Therapeutics Positive Flora Growth Positive Do analysts recommend GANX or FLGC? Gain Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 241.67%. Flora Growth has a consensus target price of $5.00, indicating a potential upside of 651.88%. Given Flora Growth's higher possible upside, analysts clearly believe Flora Growth is more favorable than Gain Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Flora Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor GANX or FLGC? Gain Therapeutics received 22 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 72.55% of users gave Gain Therapeutics an outperform vote while only 60.00% of users gave Flora Growth an outperform vote. CompanyUnderperformOutperformGain TherapeuticsOutperform Votes3772.55% Underperform Votes1427.45% Flora GrowthOutperform Votes1560.00% Underperform Votes1040.00% Which has better earnings & valuation, GANX or FLGC? Gain Therapeutics has higher earnings, but lower revenue than Flora Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,273.20-$22.27M-$1.10-2.18Flora Growth$64.15M0.20-$57.04MN/AN/A Do institutionals and insiders believe in GANX or FLGC? 12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 11.7% of Gain Therapeutics shares are owned by company insiders. Comparatively, 13.0% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, GANX or FLGC? Gain Therapeutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Is GANX or FLGC more profitable? Gain Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -30.99%. Gain Therapeutics' return on equity of -203.91% beat Flora Growth's return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -203.91% -128.05% Flora Growth -30.99%-268.17%-57.51% SummaryGain Therapeutics beats Flora Growth on 10 of the 17 factors compared between the two stocks. Remove Ads Get Flora Growth News Delivered to You Automatically Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLGC vs. The Competition Export to ExcelMetricFlora GrowthPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.93M$7.12B$5.73B$8.14BDividend YieldN/A2.77%4.41%4.10%P/E RatioN/A6.3724.1019.23Price / Sales0.20235.33419.6090.04Price / CashN/A65.6738.1134.64Price / Book0.856.636.924.38Net Income-$57.04M$141.36M$3.19B$246.90M7 Day Performance7.69%2.74%10.00%4.06%1 Month Performance-31.09%-0.73%3.13%-6.86%1 Year Performance-45.93%-3.46%15.02%5.68% Flora Growth Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLGCFlora Growth3.4501 of 5 stars$0.66-0.8%$5.00+657.6%-39.5%$12.83M$64.15M0.00280Short Interest ↓Positive NewsGANXGain Therapeutics3.0848 of 5 stars$1.86-1.1%$8.20+340.9%-44.1%$49.34M$50,000.00-1.6920Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageRPTXRepare Therapeutics3.0657 of 5 stars$1.14-3.8%$4.50+294.7%-78.5%$48.46M$53.48M-0.57180AADIAadi Bioscience1.2084 of 5 stars$1.93-9.0%$1.67-13.6%-3.2%$47.67M$25.07M-0.8540VTVTvTv Therapeutics2.4013 of 5 stars$14.89-3.3%$35.00+135.1%+26.3%$47.48M$1M-3.299Short Interest ↓News CoverageGap DownALXOALX Oncology4.0081 of 5 stars$0.89-15.7%$4.14+363.3%-93.1%$47.13MN/A-0.3040Gap UpALVRAlloVir2.31 of 5 stars$9.20-6.8%N/A-46.1%$46.39MN/A-0.45110ANEBAnebulo Pharmaceuticals3.3726 of 5 stars$1.12+4.7%$8.00+614.3%-38.6%$46.02MN/A-4.004Gap DownHigh Trading VolumeOKYOOKYO Pharma2.0657 of 5 stars$1.36-4.9%$7.00+414.7%+1.0%$46.01MN/A0.007Short Interest ↑PDSBPDS Biotechnology1.3116 of 5 stars$1.20-2.4%$11.67+872.2%-72.7%$45.83MN/A-1.0320Short Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Remove Ads Related Companies and Tools Related Companies GANX Competitors RPTX Competitors AADI Competitors VTVT Competitors ALXO Competitors ALVR Competitors ANEB Competitors OKYO Competitors PDSB Competitors NBRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLGC) was last updated on 3/18/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored92% win rate – even whe the market crashesMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flora Growth Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flora Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
